ASCO 2022 | Next-generation ALK inhibitors: treatment sequencing and resistance

Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, reflects on next-generation ALK inhibitors in non-small cell lung cancer, highlighting the importance of treatment sequencing given the availability of different ALK inhibitors, as well as potential methods to mitigate the development of resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.